Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | IP-10 | 18.0 | 60 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | IP-10 | 20.0 | 54 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | IP-10 | 17.0 | 55 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | IP-10 | 19.0 | 40 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | IP-10 | 15.0 | 43 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | IP-10 | 21.5 | 48 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | IP-10 | 921.0 | 56 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 2 | IP-10 | 286.5 | 44 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | IP-10 | 132.0 | 50 | |
N2645 | IL-1 alpha | 100 | ng/mL | 2 | IP-10 | 415.5 | 34 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | IP-10 | 194.5 | 42 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 2 | IP-10 | 181.5 | 42 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | IP-10 | 125.5 | 52 | |
RA2159 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | IP-10 | 585.0 | 50 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | IP-10 | 23.0 | 52 | |
N2645 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | IP-10 | 18.0 | 53 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | IP-10 | 28.0 | 59 | |
RA2708 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | IP-10 | 81.0 | 57 | |
RA2159 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 2 | IP-10 | 6793.0 | 69 | |
RA2159 | Poly(I:C) | 2 | ug/mL | 2 | IP-10 | 11673.0 | 51 | ||||
N2645 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 2 | IP-10 | 1112.5 | 46 | |
N2645 | Poly(I:C) | 2 | ug/mL | 2 | IP-10 | 3088.0 | 41 | ||||
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 2 | IP-10 | 4814.0 | 42 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 2 | IP-10 | 6200.5 | 36 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | 2 | IP-10 | 18.0 | 42 |